Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;100(10):1912-1915.
doi: 10.1002/ajh.70029. Epub 2025 Aug 2.

The Impact of Tirabrutinib Monotherapy for the Treatment of Bing-Neel Syndrome: A Multicenter Retrospective Study

Masuho Saburi  1 , Taro Masunari  2 , Noriko Fukuhara  3 , Yuichiro Inagaki  4 , Arika Shimura  5 , Naoto Imoto  6 , Yuta Hasegawa  7 , Masao Hagihara  8 , Nobuhiko Kobayashi  9 , Hanae Kumekawa  10 , Hideyuki Nakazawa  11 , Kana Miyazaki  12 , Toshiro Kawakita  13 , Takahiro Isshiki  14 , Atsushi Katsube  15 , Shin Fujisawa  16 , Yuichi Horigome  17 , Yusuke Koba  18 , Fumiaki Jinnouchi  19 , Naohiro Sekiguchi  20
Affiliations

The Impact of Tirabrutinib Monotherapy for the Treatment of Bing-Neel Syndrome: A Multicenter Retrospective Study

Masuho Saburi et al. Am J Hematol. 2025 Oct.
No abstract available

Keywords: Bing‐Neel syndrome; Waldenström macroglobulinemia; tirabrutinib.

PubMed Disclaimer

Conflict of interest statement

M.S. has received honoraria from Janssen and Ono. N.F. has received research grants from Abbvie, Chugai, Chordia Therapeutics, Genmab, Haihe, Incyte, Kyowa Kirin, Loxo Oncology, Ono, and Takeda, and honoraria from Abbvie, AstraZeneca, BMS, Chugai, CSL Behring, Eisai, Eli Lilly, Genmab, Janssen, Kyowa Kirin, Nippon Shinyaku, Novartis, Ono, Sanofi, Symbio, and Takeda. Y.I. has received honoraria from Kyowa Kirin, Sanofi, BMS, Jansen, Pharmaessensia, and Novartis. K.M. has received research grants or contracts from Takeda, Otsuka, Chugai, Kyowa Kirin, Sumitomo, and Zenyaku Kogyo, and honoraria from Chugai, Janssen, AstraZeneca, Novartis, Incyte, Asahi Kasei, Abbvie, SymBio, Ono, Genmab, Meiji Seika, BMS, Kyowa Kirin, Daiichi Sankyo, Gilead Sciences, and Nippon Shinyaku. Y.H. has been involved in advisory board participation with Janssen and received honoraria from Janssen, Sanofi, Ono, BMS, Takeda, CSL Behring, Novartis, and Chugai. N.S. has received honoraria from Janssen, Ono, and BeiGene, and research funding from Incyte Biosciences Japan, Janssen, Mitsubishi Tanabe Pharma Corporation, MSD, and Ono.

Figures

FIGURE 1
FIGURE 1
Outcomes of tirabrutinib treatment in 21 patients diagnosed with Bing‐Neel syndrome. A swimmer plot on the duration of tirabrutinib therapy, the time of responses to tirabrutinib, the time of tirabrutinib discontinuation, and the BNS status at the last observation period for each patient (A). Event‐free survival (EFS) (B) and overall survival (OS) (C) from tirabrutinib initiation to the last observation.
See this image and copyright information in PMC

References

    1. Simon L., Fitsiori A., Lemal R., et al., “Bing‐Neel Syndrome, a Rare Complication of Waldenström Macroglobulinemia: Analysis of 44 Cases and Review of the Literature. A Study on Behalf of the French Innovative Leukemia Organization (FILO),” Haematologica 100, no. 12 (2015): 1587–1594. - PMC - PubMed
    1. Castillo J. J., D'Sa S., Lunn M. P., et al., “Central Nervous System Involvement by Waldenström Macroglobulinaemia (Bing‐Neel Syndrome): A Multi‐Institutional Retrospective Study,” British Journal of Haematology 172, no. 5 (2016): 709–715. - PMC - PubMed
    1. Castillo J. J., Itchaki G., Paludo J., et al., “Ibrutinib for the Treatment of Bing‐Neel Syndrome: A Multicenter Study,” Blood 133, no. 4 (2019): 299–305. - PubMed
    1. Becking A. L., van de Mortel J. P. M., Tomkins O., et al., “Zanubrutinib in Bing Neel Syndrome: Efficacy and Tolerability,” Leukemia 39, no. 5 (2025): 1260–1264. - PMC - PubMed
    1. Sekiguchi N., Rai S., Munakata W., et al., “A Multicenter, Open‐Label, Phase II Study of Tirabrutinib (ONO/GS‐4059) in Patients With Waldenström's Macroglobulinemia,” Cancer Science 111, no. 9 (2020): 3327–3337. - PMC - PubMed

LinkOut - more resources